ACER has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACER has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Acer Therapeutics's Cost of Goods Sold for the three months ended in Jun. 2023 was $0.00 Mil. Acer Therapeutics's Average Total Inventories for the quarter that ended in Jun. 2023 was $2.51 Mil. Acer Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2023 was 0.00.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for Acer Therapeutics's Inventory Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acer Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Inventory Turnover | Get a 7-Day Free Trial | - | - | - | - | - |
Acer Therapeutics Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Inventory Turnover | Get a 7-Day Free Trial | - | - | - | - | - |
Acer Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2022 is calculated as
Inventory Turnover (A: Dec. 2022 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (A: Dec. 2022 ) | / ( | (Total Inventories (A: Dec. 2021 ) | + | Total Inventories (A: Dec. 2022 )) | / | count ) |
= | 0 | / ( | (0 | + | 0) | / | 1 ) |
= | 0 | / | 0 | ||||
= | N/A |
Acer Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as
Inventory Turnover (Q: Jun. 2023 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (Q: Jun. 2023 ) | / ( | (Total Inventories (Q: Mar. 2023 ) | + | Total Inventories (Q: Jun. 2023 )) | / | count ) |
= | 0 | / ( | (0.412 | + | 4.601) | / | 2 ) |
= | 0 | / | 2.5065 | ||||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acer Therapeutics (OTCPK:ACER) Inventory Turnover Explanation
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Acer Therapeutics's Days Inventory for the three months ended in Jun. 2023 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Jun. 2023 ) | / | Cost of Goods Sold (Q: Jun. 2023 ) | * | Days in Period |
= | 2.5065 | / | 0 | * | 365 / 4 | |
= |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Acer Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Jun. 2023 ) | / | Revenue (Q: Jun. 2023 ) |
= | 2.5065 | / | 0 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.
Thank you for viewing the detailed overview of Acer Therapeutics's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Chris Schelling | director, officer: President and Chief Executive | C/O ACER THERAPEUTICS INC., 222 THIRD STREET, CAMBRIDGE MA 02142 |
Steve Aselage | director | 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Tanya Hayden | officer: Chief Operating Officer | 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458 |
Adrian W Quartel | officer: Chief Medical Officer | 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458 |
Bernard H Paul | officer: Chief People Officer | 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458 |
Jefferson E Davis | officer: Chief Business Officer | 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458 |
John Michael Dunn | director | C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128 |
Donald Joseph | officer: Chief Legal Officer and Secy | C/O KALOBIOS PHARMACEUTICALS, INC., 260 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
John Michael Klopp | officer: Chief Technology Officer | ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458 |
Matthew Seibt | officer: Chief Commercial Officer | ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458 |
Michelle Renee Griffin | director | 19723 NE 65TH LANE, KIRKLAND WA 98033 |
Harry S Palmin | officer: Chief Opp. and Financial Offr | C/O NOVELOS THERAPUETICS, INC., ONE GATEWAY CENTER,SUITE 504, NEWTON MA 02458 |
William T. Andrews | officer: Chief Medical Officer | ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142 |
Jason Amello | director | 500 KENDALL STREET, CAMBRIDGE MA 01824 |
Salma Jutt-eghbali | officer: Chief Commercial Officer | ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458 |
From GuruFocus
By Tiesvg Tiesvg • 12-27-2022
By PRNewswire PRNewswire • 12-12-2022
By Marketwired • 08-30-2023
By Business Wire • 10-10-2023
By Marketwired • 08-14-2023
By PRNewswire • 08-31-2023
By sperokesalga sperokesalga • 03-17-2023
By PRNewswire • 10-13-2023
By Tiesvg Tiesvg • 12-29-2022
By GuruFocus Research GuruFocus Editor • 12-02-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.